

UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE PATENT TRIAL AND APPEAL BOARD

PROLLENIUM US INC.,
Petitioner,

v.

ALLERGAN INDUSTRIE, SAS,
Patent Owner.

Case IPR2020-00084
U.S. Patent 9,089,519

PATENT OWNER RESPONSE

TABLE OF CONTENTS

I.	INTRODUCTION	1
II.	BACKGROUND	4
A.	The POSA Faced Intricacies And Unpredictability In The Art Of Formulating Dermal Fillers.....	4
1.	Physical And Rheological Properties Must Be Accounted For	5
2.	HA Properties Affect Product Properties.....	6
3.	Crosslinkers, And The Degree Of Crosslinking, Impact The Physical And Rheological Properties	7
4.	Crosslinking Processes Introduce Additional Variables.....	9
5.	Gels Differ Between Monophasic And Biphasic.....	10
6.	Post-Crosslinking Steps Further Complicate The Process	11
7.	Degradation From Heat Sterilization Also Creates Concerns.....	12
8.	Including Lidocaine Added Complexity And Uncertainty.....	13
B.	The '519 Patent	15
III.	PERSON OF ORDINARY SKILL IN THE ART	17
IV.	CLAIM CONSTRUCTION	19
V.	PETITIONER'S ASSERTED REFERENCES	20
A.	P050047/S005	20
B.	Weinkle.....	21
C.	U.S. 2010/0028438.....	21
D.	Lebreton.....	22
E.	Sadozai	22
F.	P050047	24
G.	Kinney	24

TABLE OF CONTENTS

VI. THE PETITION IS PREMISED ON UNSUPPORTED EXPERT OPINION THAT MISCHARACTERIZES THE STATE OF THE ART AND DISPARAGES DR. LEBRETON’S DECLARATION WITHOUT BASIS25

A. Dr. DeVore Offers Opinions He Is Unable To Defend Based On Credentials He Does Not Have25

1. Dr. DeVore Concedes The Art Is Complex, Contrary To His Declaration’s Claims of “Simplicity”25

2. Dr. DeVore Applied Hindsight.....27

3. Dr. DeVore Cannot Or Will Not Explain The Chemistry28

4. Dr. DeVore Misrepresented His Credentials29

B. Dr. DeVore’s Disparagement Of Dr. Lebreton’s Declaration Is Unfounded31

VII. CLAIMS 1-4 ARE NOT ANTICIPATED (GROUNDS 1-3).....34

A. Claims 1-4 Pre-Date Petitioner’s Asserted Art35

1. The Provisional Applications Adequately Describe Claims 1-435

2. The Provisional Applications Disclose Sufficient Species To Support The Claims37

3. The ’884 Application Provides Adequate Disclosure38

B. Claims 1-4 Are Not Anticipated By P050047/S005 (Ground 1) Or Weinkle (Ground 2)39

1. Petitioner Has Not Proven P050047/S005 Is Prior Art39

2. P050047/S005 Does Not Anticipate (Ground 1)40

3. Weinkle Does Not Anticipate (Ground 2)41

VIII. CLAIMS 1-8 WOULD NOT HAVE BEEN OBVIOUS OVER LEBRETON IN VIEW OF SADOZAI (GROUND 4)41

A. The POSA Would Not Have Been Motivated To Combine Lebreton’s BDDE-Crosslinked Filler With Sadozai’s Use Of Lidocaine In Its pBCDI-Crosslinked Filler41

TABLE OF CONTENTS

B. The POSA Would Have Been Further Discouraged By
Lebreton’s And Sadozai’s Incompatible Processes46

C. The POSA Would Have Had No Reasonable Expectation Of
Success In Combining Lebreton And Sadozai.....49

D. Lebreton and Sadozai Fail To Teach The Limitations Of Claims
1-8.....51

1. It Would Not Have Been Obvious That A First BDDE-
Crosslinked HA Filler Containing Lidocaine Would
Have Performed Substantially The Same As An
Otherwise Identical Composition Without Lidocaine51

2. Lidocaine “Freely Released In Vivo” Would Not Have
Been Obvious (Claims 2, 4, 8).....53

3. Claims 5-7: The Stability Limitations Would Not Have
Been Obvious.....57

IX. CLAIMS 1-8 WOULD NOT HAVE BEEN OBVIOUS OVER
P050047 IN VIEW OF KINNEY (GROUND 5).....59

A. Petitioner Has Not Proven P050047 Is Prior Art59

B. The POSA Would Not Have Been Motivated To Combine
P050047 And Kinney60

C. The POSA Would Not Have Had A Reasonable Expectation Of
Success For Adding Lidocaine.....61

D. Petitioner’s Combination Does Not Teach The Claim
Limitations.....65

1. It Would Not Have Been Obvious That A BDDE-
Crosslinked HA Dermal Filler Containing Lidocaine
Would Have Performed Substantially The Same As An
Otherwise Identical Composition Without Lidocaine65

2. Claims 2, 4, 8: Lidocaine “Freely Released In Vivo”
Would Not Have Been Obvious66

3. Claims 5-7: The Stability Limitations Would Not Have
Been Obvious.....67

X. CONCLUSION.....69

EXHIBIT LIST

Exhibit No.	Exhibit Description
2001	Juvéderm Ultra™ XC Label
2002	Juvéderm Ultra Plus™ XC Label
2003	Juvéderm Voluma®XC Label
2004	U.S. Patent Publication No. 2004/0101959 to Marko et al, published May 27, 2004
2005	Excerpts from U.S. 8,822,676 file history
2006	Excerpts from U.S. 9,089,519 file history
2007	About Juvéderm Ultra Plus™ XC
2008	About Juvéderm Volbella® XC
2009	About Juvéderm Voluma® XC
2010	Reserved
2011	Declaration in support of unopposed motion for <i>pro hac vice</i> admission of Elizabeth Flanagan
2012	Updated Declaration in support of unopposed motion for <i>pro hac vice</i> admission of Elizabeth Flanagan
2013	Declaration of Cory J. Berkland, Ph.D
2014	Curriculum Vitae, Cory J. Berkland, Ph.D.
2015	Kuo, Practical Aspects of Hyaluronan Based Medical Products, Chs. 1-6, 2006. (“Kuo”)
2016	Hascall and Laurent, <i>Hyaluronan: Structure and Physical Properties</i> , Hyaluronan Today, Vol. 1, 1997, https://www.glycoforum.gr.jp/article/01A2.html . (“Hascall”)
2017	Cleland, et al., <i>Polyelectrolyte Properties of Sodium Hyaluronate. 2. Potentiometric Titration of Hyalyuronic Acid</i> , <i>Macromolecules</i> Vol. 15, 1982; 386-395. (“Cleland”)
2018	Knill, et al., <i>Effect of Metal Ions on the Rheological Flow Profiles of Hyaluronate Solutions</i> , Kennedy Ch. 21, <i>Hyaluronan</i> , 2002; 175-180. (“Knill”)

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.